CoChat
Sign Up
Cited by 656T-cell and B-cell ImmunologyImmunotherapy and Immune ResponsesPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin

Open access
Rao, Rajesh R., Li, Qingsheng, Odunsi, Kunle, Shrikant, Protul A.·2010·Immunity
DOI 10.1016/j.immuni.2009.10.010PMC PMC5836496
Open this paper in CoChat — free accountOpen PDF

Abstract

The mechanisms underpinning integration of instructions that program naive CD8+ T cells for effector and/or memory differentiation are not well understood. Herein, we demonstrate that interleukin-12 (IL-12) enhanced and sustained antigen and costimulatory molecule (B7.1)-induced mTOR kinase activity in naive CD8+ (OT-I) T cells via phosphoinositide 3-kinase and STAT4 transcription factor pathways. Blocking mTOR activity by rapamycin reversed IL-12-induced effector functions because of loss of persistent expression of the transcription factor T-bet. Rapamycin treatment of IL-12-conditioned OT-I cells promoted persistent Eomesodermin expression and produced memory cell precursors that demonstrated enhanced sustenance and antigen-recall responses upon adoptive transfer. The memory cell precursors showed greater tumor efficacy than IL-12-conditioned effector OT-I cells. These results identify mTOR as the central regulator of transcriptional programs that determine effector and/or memory cell fates in CD8+ T cells. Targeting mTOR activity offers new opportunities to regulate CD8+ T cell-mediated immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2009.10.010

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • TOR signaling in growth and metabolism

    Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×

    “It is possible that mTOR, which has been shown to tether several transcriptional factors (both activators and repressors) (Wullschleger et al., 2006) may regulate T-bet expression based on its activity.”
    BackgroundInfluential

  • Upstream and downstream of mTOR

    Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 2×

    “Although the kinase mTOR has been implicated as an integrator of various extracellular signals and a sensor for internal energy levels for determination of cell fate (Hay and Sonenberg, 2004), the role for mTOR in integrating instructions that program naive CD8 T cells for type I effector differentiation is unclear.”
    Background

  • A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment

    Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589 · cited 1×

    “The transcription factor T-bet (Tbx21) is the master regulator of type I effector differentiation whose expression is considerably enhanced and sustained in the presence of IL-12 (Joshi et al., 2007; Szabo et al., 2000).”
    Background

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 2×

    “Rapamycin-Treated IL-12-Conditioned OT-I Cells Demonstrate Augmented Tumor Efficacy The use of ex vivo generated tumor-antigen-specific effector CD8 T cells in adoptive cell transfer (ACT) has produced tumor regressions in the clinical setting (Morgan et al., 2006).”
    Background

  • TOR, a Central Controller of Cell Growth

    Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,914 · cited 2×

    “In agreement, with the reported role for mTOR in regulating cell size (Schmelzle and Hall, 2000) and the expression of L-type amino acid transporter (CD98) (Cornish et al.”
    Background

  • Lineage relationship and protective immunity of memory CD8 T cell subsets

    Wherry, E. J., Teichgräber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni889 · Cited by 1,864 · cited 2×

    “We performed phenotypic analysis of OT-I cells using markers associated with memory precursor CD8+ T cells, i.e., CD62L (lymph node homing) (Wherry et al., 2003), CD69 (lymph node retention) (Shiow et al., 2006), CD127 (IL-7Ra; essential for memory T cell maintenance) (Schluns et al., 2000), CD122…”
    Method

  • Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription Factor

    Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., Gapin, L., & Kaech, S. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.010 · Cited by 1,861 · cited 9×

    “Several transcription factors have been shown to coordinate and regulate the balance between long-lived memory and terminally differentiated effector CD8+ T cells (Intlekofer et al., 2005; Joshi et al., 2007; Welsh, 2009).”
    BackgroundInfluential

  • Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo

    Schluns, K. S., Kieper, W. C., Jameson, S. C., & Lefrançois, L. (2000) · Nature Immunology · doi:10.1038/80868 · Cited by 1,619 · cited 2×

    “…node homing) (Wherry et al., 2003), CD69 (lymph node retention) (Shiow et al., 2006), CD127 (IL-7Ra; essential for memory T cell maintenance) (Schluns et al., 2000), CD122 (IL-15Rb and essential for memory CD8+ T cell homeostatic renewal) (Schluns et al., 2002), KLRG1 (inversely corelated…”
    Background

  • mTOR regulates memory CD8 T-cell differentiation

    Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575

  • Enhancing CD8 T-cell memory by modulating fatty acid metabolism

    Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · cited 6×

    “…reports have demonstrated the role of mTOR in regulating CD8+ T cell trafficking (Sinclair et al., 2008) and memory differentiation (Araki et al., 2009; Pearce et al., 2009), but the molecular mechanisms by which mTOR regulates CD8+ T cell differentiation or trafficking remain uncharacterized.”
    BackgroundInfluential

Show all 41 references

Cited by

Sorted by citations

See all 656

Related

Metadata

Authors
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A.
Affiliations
Roswell Park Comprehensive Cancer Center (US)
Corresponding author
Shrikant, Protul A.
ORCID
Venue
Immunity
Publisher
Elsevier BV
Published
2010-01
Volume
32
Issue
1
Pages
67-78
ISSN
1074-7613 (ISSN-L)
DOI
10.1016/j.immuni.2009.10.010
PMC
PMC5836496
OpenAlex
W2059689009
Cited by
656
References
41
Citations by year
2026: 15 · 2025: 23 · 2024: 15 · 2023: 24 · 2022: 41 · 2021: 40 · 2020: 36 · 2019: 38 · 2018: 44 · 2017: 39 · 2016: 43 · 2015: 63 · 2014: 49 · 2013: 66 · 2012: 54
FWCI
25.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Immunity (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA158318, R01CA104645, P30CA016056)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
mTOR kinase, CD8+ T cells, T-bet, Eomesodermin, IL-12, phosphatidylinositol 3-kinase, STAT4, rapamycin, naive T cell differentiation, cancer immunotherapy
MeSH terms
T-bet Transcription Factor, Animals, Cell Differentiation, Immunologic Memory, Lymphocyte Activation, Mice, Transgenic, Transduction, Genetic, Signal Transduction, T-Lymphocyte Subsets, Protein Serine-Threonine Kinases, CD8-Positive T-Lymphocytes, T-Box Domain Proteins, Intracellular Signaling Peptides and Proteins, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review